Major vaccine trial targets vulnerable populations in africa
NCT ID NCT05168813
Summary
This study tested how well the Moderna COVID-19 vaccine worked in adults with a higher risk of severe illness, including people living with HIV. Over 14,000 participants in Eastern and Southern Africa received either two or three doses, depending on whether they had a prior COVID-19 infection. The goal was to find the most effective and practical vaccination plan for protecting these vulnerable groups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aurum Institute Klerksdorp CRS
Klerksdorp, North West, South Africa
-
Baylor-Uganda CRS
Kampala, Uganda
-
Blantyre CRS
Blantyre, Malawi
-
CAPRISA eThekwini CRS
Durban, KwaZulu-Natal, South Africa
-
Cfhrz Crs
Lusaka, Zambia
-
Clinical HIV Research Unit (CHRU)/ Helen Joseph CRS
Johannesburg, Gauteng, South Africa
-
Emavundleni CRS
Cape Town, Western Cape, South Africa
-
Eswatini Prevention Center CRS
Mbabane, Hhohho Region, Eswatini
-
FAM-CRU (Family Clinical Research Unit)
Cape Town, Western Cape, South Africa
-
Gaborone CRS
Gaborone, Botswana
-
Groote Schuur HIV CRS
Cape Town, Western Cape, South Africa
-
Isipingo CRS
Isipingo, KwaZulu-Natal, South Africa
-
Joint Clinical Research Centre
Kampala, Uganda
-
Josha Resarch CRS
Bloemfontein, Free State, South Africa
-
Kisumu - Kombewa CRS
Kisumu, 40100, Kenya
-
Kisumu Crs
Kisumu, Kenya
-
Kliptown Soweto CRS
Johannesburg, South Africa
-
MERC Kempton Park
Pretoria, Gauteng, South Africa
-
MERC Middelburg
Middelburg, Mpumalanga, South Africa
-
MERC Welkom
Welkom, South Africa
-
MU-JHU Research Collaboration CRS
Kampala, Uganda
-
Malawi CRS
Lilongwe, Malawi
-
Masiphumelele Clinical Research Site (MASI) CRS
Cape Town, Western Cape, South Africa
-
Matero Reference Clinic CRS
Lusaka, Zambia
-
MeCRU CRS
Ga-Rankuwa, Gauteng, South Africa
-
Moi University Clinical Research Centre
Eldoret, Kenya
-
Ndlovu Research Centre CoVPN CRS
Elandsdoorn, South Africa
-
Nelson Mandela Academic Research Unit CRS
Mthatha, Eastern Cape, South Africa
-
Newtown Clinical Research
Johannesburg, Gauteng, South Africa
-
PHOENIX Pharma (Pty) Ltd
Port Elizabeth, Eastern Cape, South Africa
-
PHRU Matlosana CRS
Klerksdorp, South Africa
-
Qhakaza Mbokodo Research Clinic CRS
Ladysmith, KwaZulu-Natal, South Africa
-
Rustenburg CRS
Rustenburg, North West, South Africa
-
Soweto - Bara CRS
Johannesburg, Gauteng, South Africa
-
Synergy Biomed Research Institute
East London, Eastern Cape, South Africa
-
Synexus Helderberg
Stellenbosch, Western Cape, South Africa
-
Synexus Stanza Clinical Research Centre (CRS)
Pretoria, Gauteng, South Africa
-
TASK Central
Cape Town, Western Cape, South Africa
-
TASK Eden
George, Western Cape, South Africa
-
Tembisa Clinic 4 CoVPN CRS
Tembisa, Gauteng, South Africa
-
Tongaat CRS
Durban, KwaZulu-Natal, South Africa
-
UNC Global Projects / Kamwala District Health Centre
Lusaka, Zambia
-
UVRI-IAVI HIV Vaccine Program LTD. CRS
Entebbe, Uganda
-
Univeristy of Cape Town Lung CRS Institute
Cape Town, Western Cape, South Africa
-
Vulindlela CRS
Durban, KwaZulu-Natal, South Africa
-
Wits RHI Ward 21 CRS
Johannesburg, Gauteng, South Africa
-
Zambia Emory HIV Research Project - Ndola CoVPN CRS
Ndola, Zambia
Conditions
Explore the condition pages connected to this study.